BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37473460)

  • 1. Generation of gene corrected human isogenic iPSC lines (IDVi003-A_CR13, IDVi003-A_CR21, IDVi003-A_CR24) from an inherited retinal dystrophy patient-derived IPSC line ITM2B-5286-3 (IDVi003-A) carrying the ITM2B c.782A > C variant using CRISPR/Cas9.
    Ben Yacoub T; Letellier C; Wohlschlegel J; Condroyer C; Slembrouck-Brec A; Goureau O; Zeitz C; Audo I
    Stem Cell Res; 2023 Sep; 71():103166. PubMed ID: 37473460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of human induced pluripotent stem cell lines from a patient with ITM2B-related retinal dystrophy and a non mutated brother.
    Wohlschlegel J; Letellier C; Liu B; Méjécase C; Slembrouck-Brec A; Condroyer C; Michiels C; Sahel JA; Reichman S; Zeitz C; Goureau O; Audo I
    Stem Cell Res; 2019 Dec; 41():101625. PubMed ID: 31731182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The familial dementia gene revisited: a missense mutation revealed by whole-exome sequencing identifies ITM2B as a candidate gene underlying a novel autosomal dominant retinal dystrophy in a large family.
    Audo I; Bujakowska K; Orhan E; El Shamieh S; Sennlaub F; Guillonneau X; Antonio A; Michiels C; Lancelot ME; Letexier M; Saraiva JP; Nguyen H; Luu TD; Léveillard T; Poch O; Dollfus H; Paques M; Goureau O; Mohand-Saïd S; Bhattacharya SS; Sahel JA; Zeitz C
    Hum Mol Genet; 2014 Jan; 23(2):491-501. PubMed ID: 24026677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of two induced pluripotent stem cell lines (TMOi001-A-5, TMOi001-A-6) carrying variants in DISC1 exon 2 using CRISPR/Cas9 gene editing.
    Heider J; Sperlich D; Vogel S; Breitmeyer R; Volkmer H
    Stem Cell Res; 2022 Oct; 64():102925. PubMed ID: 36154917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation and characterization of a human iPSC line and gene-corrected isogenic line derived from a patient with a CELF2 gene mutation.
    Hua M; Williams L; Burns K; Liu S; Ellis J; Innes AM; McPherson M; Yang G
    Stem Cell Res; 2024 Apr; 76():103344. PubMed ID: 38364506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of a gene corrected human isogenic iPSC line (CPGHi001-A-1) from a hearing loss patient with the TMC1 p.M418K mutation using CRISPR/Cas9.
    Wang H; Luo Y; Li J; Guan J; Yang S; Wang Q
    Stem Cell Res; 2022 Apr; 60():102736. PubMed ID: 35247837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of a gene corrected human isogenic IBMS-iPSC-014-C from polycystic-kidney-disease induced pluripotent stem cell line using CRISPR/Cas9.
    Liu CL; Huang CY; Chen HC; Lu HE; Hsieh PCH; Lee JJ
    Stem Cell Res; 2020 May; 45():101784. PubMed ID: 32361310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determining the Pathogenicity of a Genomic Variant of Uncertain Significance Using CRISPR/Cas9 and Human-Induced Pluripotent Stem Cells.
    Ma N; Zhang JZ; Itzhaki I; Zhang SL; Chen H; Haddad F; Kitani T; Wilson KD; Tian L; Shrestha R; Wu H; Lam CK; Sayed N; Wu JC
    Circulation; 2018 Dec; 138(23):2666-2681. PubMed ID: 29914921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of a gene-corrected human isogenic line (UAMi006-A) from propionic acidemia patient iPSC with an homozygous mutation in the PCCB gene using CRISPR/Cas9 technology.
    Fulgencio-Covián A; Álvarez M; Pepers BA; López-Márquez A; Ugarte M; Pérez B; van Roon-Mom WMC; Desviat LR; Richard E
    Stem Cell Res; 2020 Dec; 49():102055. PubMed ID: 33128956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of two isogenic knockout PKD2 iPS cell lines, IRFMNi003-A-1 and IRFMNi003-A-2, using CRISPR/Cas9 technology.
    Trionfini P; Ciampi O; Romano E; Benigni A; Tomasoni S
    Stem Cell Res; 2020 Jan; 42():101667. PubMed ID: 31830647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation and characterization of two iPSC lines carrying heterozygous or homozygous nonsense mutation in PROM1 gene from a single family.
    Xu P; Guo F; Xie B; Zhong X
    Stem Cell Res; 2022 Oct; 64():102913. PubMed ID: 36191543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of a gene-corrected isogenic iPSC line (AHQUi001-A-1) from a patient with familial hypertriglyceridemia (FHTG) carrying a heterozygous p.C310R (c.928 T > C) mutation in LPL gene using CRISPR/Cas9.
    Sun X; Zhou X; Dong B; Wang C; Xiao X; Wang Y
    Stem Cell Res; 2021 Apr; 52():102230. PubMed ID: 33592566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling of dilated cardiomyopathy by establishment of isogenic human iPSC lines carrying phospholamban C25T (R9C) mutation (UPITTi002-A-1) using CRISPR/Cas9 editing.
    Barndt RJ; Ma N; Tang Y; Haugh MP; Alamri LS; Chan SY; Wu H
    Stem Cell Res; 2021 Oct; 56():102544. PubMed ID: 34583280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of an induced pluripotent stem cell line LEIi019-A from an early-onset retinal dystrophy patient with the autosomal dominant OTX2 c.259G>A variant.
    Zhang D; Jennings L; Chen SC; Zaw K; Lamey TM; Thompson JA; McLaren TL; Chen FK; McLenachan S
    Stem Cell Res; 2024 Aug; 78():103461. PubMed ID: 38852423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of a pluripotent stem cell line (UMGi270-A) and a corresponding CRISPR/Cas9 modified isogenic control (UMGi270-A-1) from a patient with sudden onset dilated cardiomyopathy harboring a FLNC p.R2187P mutation.
    Maurer W; Rebs S; Köhne S; Eberl H; Wollnik B; Zibat A; Streckfuss-Bömeke K
    Stem Cell Res; 2024 Jun; 77():103409. PubMed ID: 38583294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of simultaneous reprogramming and gene correction to generate an osteogenesis imperfecta patient COL1A1 c. 3936 G>T iPSC line and an isogenic control iPSC line.
    Howden S; Hosseini Far H; Motazedian A; Elefanty AG; Stanley EG; Lamandé SR; Bateman JF
    Stem Cell Res; 2019 Jul; 38():101453. PubMed ID: 31082677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of CRISPR-Cas9 edited human induced pluripotent stem cell line carrying BAG3 V468M mutation in its BAG domain.
    Duboscq-Bidot L; Hoareau B; Ader F; Fontaine V; Villard E
    Stem Cell Res; 2024 Feb; 74():103294. PubMed ID: 38183888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of a heterozygous COL2A1 (p.G1113C) hypochondrogenesis mutation iPSC line, MCRIi019-A-7, using CRISPR/Cas9 gene editing.
    Lilianty J; Bateman JF; Lamandé SR
    Stem Cell Res; 2021 Oct; 56():102515. PubMed ID: 34543885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of a ST3GAL3 null mutant induced pluripotent stem cell (iPSC) line (UKWMPi002-A-3) by CRISPR/Cas9 genome editing.
    Diouf D; Vitale MR; Zöller JEM; Pineau AM; Klopocki E; Hamann C; Ziegler GC; Vanmierlo T; Van den Hove D; Lesch KP
    Stem Cell Res; 2023 Mar; 67():103038. PubMed ID: 36746102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of an induced pluripotent stem cell line from a patient with global development delay carrying DYRK1A mutation (c.1730T>A) and a gene correction isogenic iPSC line.
    Ma L; Wu Z; Tang Q; Ji X; Mei Y; Peng T; Xu Q; Zhou W; Xiong M
    Stem Cell Res; 2021 May; 53():102305. PubMed ID: 33813175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.